Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 23

1747P - The need for a better discussion between doctors and patients with regards to fertility preservation and vaginal rehab after anti cervical cancer treatments

Date

21 Oct 2023

Session

Poster session 23

Topics

Patient Education and Advocacy;  Cancer in Adolescents and Young Adults (AYA);  Cancer and Pregnancy;  Cancer Care Equity Principles and Health Economics;  Cancer Prevention;  Survivorship

Tumour Site

Cervical Cancer

Presenters

Bar Levy

Citation

Annals of Oncology (2023) 34 (suppl_2): S925-S953. 10.1016/S0923-7534(23)01945-2

Authors

B. Levy1, V. Ben Hur Peer1, O. Shaul2, O. Erlich2, Z. Magen2

Author affiliations

  • 1 Management, Habit Shel Bar - Israel Women's Cancer Association (RA), 6958312 - Tel Aviv/IL
  • 2 Management, HaBait Shel Bar - Israel’s Women’s Cancer Association (RA), 6958312 - Tel Aviv/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1747P

Background

Cervical cancer patients' age is relatively young (considering only 35-39 and not 60-64). At this young age, patients might consider birth planning and other sexual health considerations such as vaginal rehabilitation.

Methods

A call for answers to a survey was published and patients and verified survivors were invited to respond voluntarily and anonymously through a coded and encrypted web form.

Results

116 women responded to the survey (age 21-72, median=42, age range at diagnosis 18-65). 8% were diagnosed with CIN1-2, 43% with CIN3, 20% with stage 1, 7% with stage 2, 10% with stages 3-4, 12% did not know how to answer. Past treatments were recorded. 84% of those required to use a vaginal dilator did not do so (results were modified in accordance to guidelines). At childbearing age [67 women, ages 21-45, median=37; 55.22% CIN3, 19.4% stage 1, 5.97% stage 2, 5.97% stages 3-4, 13.43% did not know how to answer; 77.61% were sexually active with a single known partner], only 58.2% recall having a discussion with their physician regarding fertility preservation, before beginning treatments. 32.83% recall such a discussion afterwards. 11.94% give birth after illness or had a child thanks to a surrogate mother.

Conclusions

This study underscores the need for greater attention to patients’ sexual health and fertility aspects before and after completion of treatments. There is a need in coordinate patients' expectations regarding birth planning and in making the information regarding vaginal dilator accessible. Research involving a larger sample size may help to better support the information needs of survivors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

HaBait Shel Bar – Israel’s Women’s Cancer Association (RA).

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.